Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00996723 | Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) | PHASE1 | COMPLETED | 25 | — | — | Oct 1, 2009 | Jun 1, 2014 | Apr 6, 2015 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| vandetanib and dasatinib | DRUG | Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG. |
Inclusion Criteria: 1. Age must be ≥ 18 months and \< 21 years 2. Diagnosis of DIPG or high-grade glioma originating from the brainstem. 3. Lansky (for research participants ≤ 16 years) or Karnofsky (for research participants \> 16 years) performance score ≥ 40 at the time of study enrollment 4. Ad...